Dianthus therapeutics announces fda clearance to initiate phase 2 trial of dnth103 in multifocal motor neuropathy (mmn)

Top-line results from phase 2 momentum trial in multifocal motor neuropathy anticipated in 2h 2026 building a neuromuscular franchise with dnth103 following the initiation of the phase 2 magic trial in generalized myasthenia gravis (gmg) in 1q'24 and planned initiation of a phase 2 trial in chronic inflammatory demyelinating polyneuropathy (cidp) in 2h'24 recently disclosed head-to-head affinity and pd potency data reinforce dnth103 is a highly potent, potential best-in-class active c1s inhibitor designed for self-administration in a low-volume, subcutaneous autoinjector once every two weeks new york and waltham, mass., june 12, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced u.s. food and drug administration (fda) clearance of its phase 2 investigational new drug (ind) application for the momentum trial of dnth103 in patients with multifocal motor neuropathy (mmn).
DNTH Ratings Summary
DNTH Quant Ranking